17:54 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies identified a cyclic lipodepsipeptide (CLD) that could help treat cancer. In mice with mouse embryo fibroblast-induced foot tumors, a previously reported CLD containing a 4-amido-2,4-pentadienoate substructure decreased tumor growth compared with vehicle....
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Patient sample and cell culture studies suggest nitro-fatty acids could help treat STING-associated vasculopathy with onset in infancy (SAVI), an inflammatory disease caused by gain-of-function STING mutations. In fibroblasts from SAVI patients, nitro-fatty acids...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
22:57 , Mar 5, 2018 |  BC Extra  |  Preclinical News

HIV shock and kill combo shows promise in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
19:21 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a Kd of 1.4...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod...
23:03 , Aug 9, 2017 |  BC Extra  |  Clinical News

Mologen sinks on lefitolimod HIV miss

Mologen AG (Xetra:MGN) dropped €0.81 (21%) to €3.06 on Wednesday after its lefitolimod (MGN1703) missed the primary endpoint in an extension of the Phase Ib/IIa TEACH trial to treat HIV infection in patients on antiretroviral...
23:05 , Feb 2, 2017 |  BC Innovations  |  Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD163

Neurology INDICATION: Parkinson's disease (PD) Rat studies suggest CD163-targeting liposomes loaded with anti-inflammatory agents could help treat PD. In a rat model of PD, numbers of striatum-infiltrating CD163-positive macrophages were higher than in normal rats. In the...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...